Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

    February 2023 in “Advances in Therapy
    Peter C Taylor, Thomas Bieber, Rieke Alten, Torsten Witte, James Galloway, Walter Deberdt, Maher Issa, Ewa Haladyj, Inmaculada de la Torre, Susanne Grond, Andreas Wollenberg
    TLDR Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
    The document analyzes the safety of Baricitinib, a medication used for treating rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). The study pooled data from clinical trials and long-term extensions, involving 7709 patients and up to 9.3 years of exposure. The study found that patients with low risk factors had low incidence rates of major adverse cardiovascular events, malignancies, venous thromboembolism, serious infection, and mortality. Even in patients with risk factors, the incidence rates were low for dermatologic indications. The study concludes that considering individual disease burden, risk factors, and response to treatment is important for making informed decisions for patients treated with Baricitinib. For AA, baricitinib has demonstrated significant hair regrowth in clinical trials.
    View this study on link.springer.com →

    Cited in this study